RESUMEN
Peripheral T-cell lymphoma (PTCL) is a group of highly heterogeneous rare malignant lymphoproliferative diseases, and PTCL patients have low therapeutic efficacy rate and poor prognosis after conventional comprehensive treatments. Hematopoietic stem cell transplantation (HSCT) can improve the survival of PTCL patients, and previous studies showed that patients with a definite diagnosis should receive high-dose chemotherapy combined with autologous-HSCT (auto-HSCT) in the first remission. In recent years, a consensus on the role of auto-HSCT as the first-line consolidation therapy for PTCL patients has not been reached so far. Allogeneic-HSCT is an effective option for relapsed and refractory patients with PTCL, while auto-HSCT has unfavorable efficacies. This paper reviews the research progress of HSCT in treatment of PTCL.